Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 2 | 2017 | 46 | 1.110 |
Why?
|
| Postoperative Complications | 4 | 2017 | 780 | 0.680 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2018 | 2 | 0.630 |
Why?
|
| Nephrons | 1 | 2018 | 10 | 0.630 |
Why?
|
| Urinary Tract Infections | 3 | 2017 | 45 | 0.620 |
Why?
|
| Hemorrhage | 1 | 2018 | 100 | 0.590 |
Why?
|
| Disease Management | 1 | 2018 | 126 | 0.580 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2017 | 198 | 0.570 |
Why?
|
| Nephrectomy | 1 | 2018 | 123 | 0.570 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 42 | 0.560 |
Why?
|
| Vagina | 1 | 2017 | 59 | 0.560 |
Why?
|
| Surgical Mesh | 1 | 2017 | 48 | 0.550 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2017 | 47 | 0.550 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 84 | 0.540 |
Why?
|
| Pheochromocytoma | 1 | 2015 | 6 | 0.520 |
Why?
|
| Catecholamines | 1 | 2015 | 18 | 0.520 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 15 | 0.510 |
Why?
|
| Internship and Residency | 1 | 2017 | 311 | 0.450 |
Why?
|
| Urinary Tract | 1 | 2013 | 22 | 0.450 |
Why?
|
| Urologic Diseases | 1 | 2013 | 27 | 0.450 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2013 | 155 | 0.400 |
Why?
|
| Urinary Calculi | 1 | 2011 | 7 | 0.400 |
Why?
|
| Urine | 1 | 2011 | 65 | 0.380 |
Why?
|
| Ureter | 1 | 2011 | 38 | 0.380 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 241 | 0.370 |
Why?
|
| Mineral Oil | 1 | 2010 | 4 | 0.370 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2010 | 7 | 0.370 |
Why?
|
| Sclerosis | 1 | 2010 | 10 | 0.370 |
Why?
|
| Penis | 1 | 2010 | 35 | 0.360 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 259 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 458 | 0.350 |
Why?
|
| Middle Aged | 9 | 2018 | 11834 | 0.340 |
Why?
|
| Kidney | 1 | 2011 | 518 | 0.290 |
Why?
|
| Neoplasms | 1 | 2013 | 728 | 0.270 |
Why?
|
| Databases, Factual | 2 | 2017 | 354 | 0.260 |
Why?
|
| Retrospective Studies | 5 | 2017 | 3505 | 0.250 |
Why?
|
| Female | 9 | 2018 | 19999 | 0.250 |
Why?
|
| Humans | 14 | 2018 | 32082 | 0.250 |
Why?
|
| Aged | 4 | 2017 | 10308 | 0.180 |
Why?
|
| Prognosis | 2 | 2015 | 1496 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2263 | 0.160 |
Why?
|
| Adult | 6 | 2016 | 9375 | 0.160 |
Why?
|
| Male | 7 | 2017 | 19202 | 0.150 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2017 | 2 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 6 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cystocele | 1 | 2017 | 4 | 0.150 |
Why?
|
| Hernia | 1 | 2017 | 11 | 0.150 |
Why?
|
| Pelvic Floor | 1 | 2017 | 19 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2013 | 2282 | 0.140 |
Why?
|
| Uterine Prolapse | 1 | 2017 | 21 | 0.140 |
Why?
|
| Reoperation | 1 | 2017 | 226 | 0.140 |
Why?
|
| Young Adult | 2 | 2015 | 2665 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2017 | 126 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 516 | 0.140 |
Why?
|
| Nephrolithiasis | 1 | 2016 | 2 | 0.140 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2015 | 1 | 0.130 |
Why?
|
| Vertigo | 1 | 2015 | 3 | 0.130 |
Why?
|
| Dizziness | 1 | 2015 | 12 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 58 | 0.130 |
Why?
|
| Bioengineering | 1 | 2015 | 70 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2017 | 895 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 190 | 0.110 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 201 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3304 | 0.100 |
Why?
|
| Kidney Calculi | 1 | 2012 | 23 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 447 | 0.100 |
Why?
|
| Specific Gravity | 1 | 2011 | 2 | 0.100 |
Why?
|
| Hardness | 1 | 2011 | 5 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 923 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 560 | 0.100 |
Why?
|
| Magnesium | 1 | 2011 | 30 | 0.100 |
Why?
|
| Sodium | 1 | 2011 | 40 | 0.100 |
Why?
|
| Potassium | 1 | 2011 | 40 | 0.100 |
Why?
|
| Nitrofurantoin | 1 | 2011 | 3 | 0.100 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 105 | 0.100 |
Why?
|
| Creatinine | 1 | 2011 | 196 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 876 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 517 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 543 | 0.090 |
Why?
|
| Laos | 1 | 2010 | 3 | 0.090 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 4 | 0.090 |
Why?
|
| Men's Health | 1 | 2010 | 12 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2009 | 27 | 0.090 |
Why?
|
| Antioxidants | 1 | 2009 | 114 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 70 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2010 | 182 | 0.080 |
Why?
|
| Cholesterol | 1 | 2009 | 252 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 244 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 917 | 0.070 |
Why?
|
| Tissue Engineering | 1 | 2010 | 656 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2009 | 766 | 0.060 |
Why?
|
| Adolescent | 1 | 2011 | 3568 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1128 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 198 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2015 | 28 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 581 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 3880 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2015 | 238 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2015 | 198 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 313 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 209 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2012 | 9 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 21 | 0.020 |
Why?
|
| Seeds | 1 | 2009 | 10 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2009 | 38 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 95 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 996 | 0.020 |
Why?
|
| Regeneration | 1 | 2010 | 170 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 185 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 313 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 415 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 846 | 0.020 |
Why?
|